Daiichi Sankyo Co., Ltd.’s HER2-directed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been approved in Japan, for the treatment of patients with HER2-positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
The Japanese firm’s lead ADC asset, which links an HER2 antibody and topoisomerase I inhibitor payload, is already approved in...






